Compare · ABBV vs JAZZ
ABBV vs JAZZ
Side-by-side comparison of AbbVie Inc. (ABBV) and Jazz Pharmaceuticals plc (JAZZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and JAZZ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $449.63B, about 28.9x JAZZ ($15.55B).
- Over the past year, ABBV is up 33.1% and JAZZ is up 115.4% - JAZZ leads by 82.3 points.
- ABBV has been more active in the news (23 items in the past 4 weeks vs 9 for JAZZ).
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- Jazz Pharmaceuticals plc
- Price
- $254.52+0.06%
- $247.51+2.29%
- Market cap
- $449.63B
- $15.55B
- 1M return
- +14.38%
- +9.12%
- 1Y return
- +33.08%
- +115.41%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2007
- News (4w)
- 23
- 9
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest JAZZ
- Canaccord Genuity initiated coverage on Jazz Pharma with a new price target
- SEC Form DEFA14A filed by Jazz Pharmaceuticals plc
- Director Cozadd Bruce C sold $1,442,820 worth of Ordinary Shares (6,000 units at $240.47) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 366,682 units (SEC Form 4)
- EVP, Chief Commercial Officer Pearce Samantha covered exercise/tax liability with 2,527 units of Ordinary Shares, decreasing direct ownership by 5% to 47,911 units (SEC Form 4) (tax liability)
- President & CEO Gala Renee D covered exercise/tax liability with 4,835 units of Ordinary Shares, decreasing direct ownership by 3% to 147,361 units (SEC Form 4) (withholding tax)
- EVP, Global Head of R&D & CMO Iannone Robert covered exercise/tax liability with 3,764 units of Ordinary Shares, decreasing direct ownership by 4% to 85,107 units (SEC Form 4) (for tax liability)
- EVP & Chief Legal Officer Patil Neena M covered exercise/tax liability with 2,678 units of Ordinary Shares, decreasing direct ownership by 5% to 48,871 units (SEC Form 4) (withholding obligation)
- EVP & Chief Financial Officer Johnson Philip L covered exercise/tax liability with 3,343 units of Ordinary Shares, decreasing direct ownership by 6% to 56,431 units (SEC Form 4) (withholding tax)
- SEC Form 144 filed by Jazz Pharmaceuticals plc
- Director Smith Mark Douglas sold $266,746 worth of Ordinary Shares (1,157 units at $230.55) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 9,680 units (SEC Form 4)